June 9th, 2014
＜News Release＞
Pharmaceutical Research and Manufacturers of America (PhRMA)
European Federation of Pharmaceutical Industries and Associations (EFPIA)

US and European Pharmaceutical Firms conducting 682 clinical trials
at 11,653 sites throughout Japan to develop innovative medicines
for Japanese patients
PHRMA and EFPIA member companies spend 88 billion yen on clinical trials in Japan,
Saw approvals of 15 new drugs in 2013
PhRMA and EFPIA issued the joint report on the current situation of clinical research by foreign capital
pharmaceutical companies in Japan, which titled “Research in Your Backyard” contains the data ofresearches for developing new drugs, which is available for each of the 47 prefectures and each of the16 diseases supported by them.
The contributions made to Japan by foreign pharmaceutical companies as shown by this report are
mainly as follows;

PhRMA and EFPIA member companies conduct 682 clinical trials in 11,653 sites yearly across all
prefectures of Japan
PhRMA and EFPIA member companies
carried out 682 clinical trials in 11,653
sites throughout the country in single
year of 2013.

These involved morethan 16 therapeutic areas, including
cancer, allergy, cardiology,gastroenterology, and rare diseases.
In the past 7 years, 132 new drugs fromPhRMA and EFPIA companies wereapproved in Japan, including 15 drugs
approved in 2013. To provide access to innovative drugs to patients in a timely manner, PhRMA andEFPIA members are increasing simultaneous global development including Japan to reduce the “druglag."

The total clinical-related spending by PhRMA and EFPIA companies in Japan was 88 billion yen.
The total clinical-related spending by all
pharmaceutical companies in Japan was 247billion yen in 1,306 billion yen for allpharmaceutical R&D Spending in 2012.
Of this, PhRMA and EFPIA companies
spending was 88 billion and this spending
and investment is spread throughout thenation.

PhRMA and EFPIA think how these trials benefit Japan as follows;.
First, medical facilities conducting clinical trials are able to provide advanced medical treatments to theirpatients, which mean to improve the quality of life for local patients.

This is possible only because ofphysicians’ participation in the trials.
Second, the spending on clinical trials in Japan goes to hospitals and clinics nationwide and supports theeconomy in every prefecture.
Third, these clinical trials create jobs throughout Japan as local medical facilities, pharmaceuticalcompanies, SMO and CRO employ local staff to support clinical trials.

And most of those jobs are highskilled, high paid, high value-added jobs.

These clinical trials represent the intellectual base of pharmaceutical industry.
industry is in the intellectual property they put into drug development.

The value added of thisTo sustain these investments,

however, it is necessary to have supportive government policies in the areas of drug approval andpricing and reimbursement.

PhRMA and EFPIA hope the related governmental offices in Japan will

support these policies that are necessary to stimulate economic growth in Japan and provide theworld’s best medicines to Japanese patients.

*An iBook version of the report is also prepared for utilizing the data by iPad in where needed scenes,
such as a presentation.

Please see the whole report below, if you need.

http://www.phrma-jp.org/





PhRMA Tokyo Office Website
PhRMA Website
EFPIA JAPAN Website
EFPIA Website

http://www.phrma-jp.org
http://www.phrma.org
http://efpia.jp/index.html
http://www.efpia.eu/

For any media inquiries,
Contact Mitani, Aoki, Murata, Saiki at PhRMA PR Office (at Japan Counselors Inc.)
Tel: +81-3-3291-0118
Fax: 81-3-3291-0223
E-mail: phrma_pr@jc-inc.co.jp